קרסטור   20 מג ישראל - עברית - Ministry of Health

קרסטור 20 מג

astrazeneca (israel) ltd - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 20 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

קרסטור   40 מג ישראל - עברית - Ministry of Health

קרסטור 40 מג

astrazeneca (israel) ltd - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 40 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

 קרסטור  5 מג ישראל - עברית - Ministry of Health

קרסטור 5 מג

astrazeneca (israel) ltd - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 5 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

אירסה  ישראל - עברית - Ministry of Health

אירסה

astrazeneca (israel) ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib - gefitinib - iressa is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from iressa. results from two large controlled randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding iressa to doublet platinum-based chemotherapy.iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk.

זולדקס אל.אי. ישראל - עברית - Ministry of Health

זולדקס אל.אי.

astrazeneca (israel) ltd - goserelin as acetate - שתל להזרקה - goserelin as acetate 10.8 mg/unit - goserelin - goserelin - prostate cancer suitable for hormonal manipulation.

זולדקס ישראל - עברית - Ministry of Health

זולדקס

astrazeneca (israel) ltd - goserelin as acetate - שתל - goserelin as acetate 3.6 mg/unit - goserelin - goserelin - treatment of prostate cancer suitable for hormonal manipulation. breast cancer in pre-menopausal women suitable for hormone manipulation.endometriosis. assisted reproduction: pituitary down regulation in preparion for superovulation. endometrial thinning: zoladex is indicated for the prethinning of the utetine endometrium prior ro endometrial ablation or resection. uterine fibroids: for reduction of fibroid size prior to surgery.

פסלודקס ישראל - עברית - Ministry of Health

פסלודקס

astrazeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.

זומיג 2.5 מג ישראל - עברית - Ministry of Health

זומיג 2.5 מג

astrazeneca (israel) ltd - zolmitriptan - טבליות מצופות פילם - zolmitriptan 2.5 mg - zolmitriptan - zolmitriptan - acute treatment of migraine with or without aura.

סימביקורט טורבוהלר 804.5 מקגמנה ישראל - עברית - Ministry of Health

סימביקורט טורבוהלר 804.5 מקגמנה

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 80 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. note: symbicort turbuhaler 80/4.5 mcg/dose is not appropriate in patients with severe asthma.

סימביקורט טורבוהלר 1604.5 מקגמנה ישראל - עברית - Ministry of Health

סימביקורט טורבוהלר 1604.5 מקגמנה

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 160 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - asthma symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents age 12 years and above where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. or - patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.